Asymchem Laboratories (Tianjin) (002821) Stock Price, Fundamentals & Analysis

What 002821 does

Asymchem Laboratories (Tianjin) (002821) is a contract development and manufacturing organization (CDMO) that provides end-to-end pharmaceutical services across Mainland China and internationally. It works on small molecule CDMO projects in areas such as oncology, antiviral, anti-infective, cardiovascular, and diabetes, and also offers chemical macromolecule CDMO, biomacromolecule CDMO (including antibody-peptide conjugates), formulation CDMO, clinical CRO, synthetic biology, and new technology output services. The company is also involved in key pharmaceutical intermediates, APIs, and formulations. Founded in 1998 and headquartered in Tianjin, China, it operates in the Healthcare sector under the Biotechnology industry on the Shenzhen Stock Exchange.

Key numbers explained

• The current price of 178.3 CNY reflects the latest trading value; a -5.17% price change today indicates a short-term decline.
• The trailing P/E ratio of 61.1 compares the price to the last 12 months of earnings per share (2.92 CNY), while the forward P/E ratio of 34.9 uses expected future earnings.
• The dividend yield of 0.73% shows the annual dividend relative to the price, with 44% of earnings paid out as dividends and an ex-dividend date of Jun 26, 2026.
• Beta of 0.13 suggests the stock has historically moved much less than the overall market.
• The 52-week range of 88.46 – 200 and a 62.2% price change over the last 52 weeks illustrate the recent price journey.
• The price-to-book ratio of 3.57 compares the market price to the company's book value per share.
• Revenue of 7.09 mld. CNY with 9.6% year-over-year growth, a 14.6% profit margin, and a 17.5% operating margin describe the scale and efficiency of operations.
• The debt-to-equity ratio of 2 indicates the company carries twice as much debt as equity.

What to watch

Investors tracking Asymchem Laboratories (Tianjin) (002821) may monitor CDMO industry trends, as demand for contract manufacturing services often follows pharmaceutical R&D cycles and global healthcare spending. Regulatory changes in Mainland China and international markets can affect approval timelines and margins. The company's exposure to multiple therapy areas, including oncology and antiviral, may influence how it responds to shifts in drug development pipelines. Broader Shenzhen Stock Exchange dynamics and sector rotation within Healthcare can also affect valuation multiples and trading volume.